Richtig G, Wolf M, Schulter G, et al. Body-Mass-Index as a predictive marker for response in patients with metastatic melanoma treated with ipilimumab. SMR 2017, P01-15.
I-SPY2: voordeel van toevoegen pembrolizumab aan neoadjuvante chemotherapie
mrt 2020 | Borstkanker